Novo Nordisk has officially launched its weight loss medication Wegovy in China. This move opens access to over 500 million potential candidates for treatment by 2045.
Regulatory approval and market potential
Chinese authorities approved Wegovy at the end of June, and the Danish pharmaceutical giant is now introducing it to the market. The Chinese business media outlet Yican reports that the first patient will receive a prescription for Wegovy in Shanghai this week, a detail confirmed by Reuters.
To qualify for Wegovy in China, individuals must have a Body Mass Index (BMI) of at least 30 and suffer from at least one weight-related health condition. Currently, many citizens meet these criteria, as there are 184 million severely overweight individuals in China. This figure is expected to rise to 500 million by 2045, presenting enormous market potential.
Impact of competition and brand strength
Despite Wegovy’s patent expiration in a few years and the emergence of copycat products from Chinese manufacturers, Novo’s sales in China may not significantly decline. Producing medicine at Novo’s scale requires substantial investment, which creates a floor on pricing for potential competitors.
Additionally, Novo enjoys a strong reputation and established connections within the diabetes treatment network in China. These relationships will help the company successfully introduce Wegovy to the market.
Initial access and future plans
Initially, Novo Nordisk will offer Wegovy mainly to patients willing to pay out-of-pocket, without relying on health insurance. This approach mirrors practices seen in other countries and ensures that enough medication remains available for those who have begun treatment.
Furthermore, Novo will likely seek to include Wegovy in subsidy programs as production capacity grows. This inclusion would allow the medication to reach an even larger patient base.
In March, Novo announced plans to invest over $500 million to expand its existing facility in Tianjin, China. This investment will enhance its production capabilities. As the company moves forward, it aims to make a significant impact in the fight against obesity in China while establishing itself in the growing weight loss market.
Furthermore Novo Nordisk has officially launched its weight loss medication Wegovy in China. This move opens access to over 500 million potential candidates for treatment by 2045.
Source: B.T.
[…] Chinese authorities approved Wegovy in late JuneNovo is positioned to address rising rates of obesity and diabetes in the population. In the initial […]